Hiromi Nara

Title: Hiromi Nara: Innovator in Antibody Development

Introduction

Hiromi Nara is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical applications. With a total of 2 patents, Nara's work focuses on innovative solutions for serious health conditions.

Latest Patents

Nara's latest patents include an anti-human Tie2 antibody designed to prevent or treat diabetic macular edema, diabetic retinopathy, and critical limb ischemia. This antibody works by binding to human Tie2 to activate it. The invention comprises four heavy chain variable regions and four light chain variable regions. The heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, while the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4. Each heavy chain variable region and light chain variable region together form one antigen-binding site, resulting in an antibody with four antigen-binding sites.

Career Highlights

Hiromi Nara is currently associated with Astellas Pharma GmbH, where he continues to advance his research in antibody development. His work has the potential to significantly impact the treatment of various eye diseases and vascular conditions.

Collaborations

Nara collaborates with notable colleagues, including Masazumi Kamohara and Shigenori Yagi, who contribute to his research efforts and innovations.

Conclusion

Hiromi Nara's contributions to the field of biotechnology through his innovative patents highlight his role as a key inventor in the development of therapeutic antibodies. His work promises to enhance treatment options for patients suffering from critical health issues.